Alastin Skincare announced that the U.S. Patent and Trademark Office has issued a fourth U.S. Patent, No. 10,688,147, incorporating Alastin's platform TriHex Technology. The patent is directed to a topical composition for alleviating bruising caused by a cosmetic procedure—INhance Post-Injection Serum with TriHex Technology. "We are immensely proud of the scientific investment we have made in validating TriHex Technology performance in our product formulations which is confirmed by its numerous patents," says Alan Widgerow, M.D., FACS, and chief medical officer at Alastinn. "INhance Post-Injection Serum combines the anti-aging benefits of patented TriHex Technology and our new ChromaFADE Technology to deliver state-of-the-art post-procedure recovery and skin-enhancing benefits."
the Latest Issue